Horigome Ayako, Hisata Ken, Odamaki Toshitaka, Iwabuchi Noriyuki, Xiao Jin-Zhong, Shimizu Toshiaki
Next Generation Science Institute, Morinaga Milk Industry Co., Ltd., Kanagawa, Japan.
Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan.
Front Microbiol. 2021 Apr 7;12:610080. doi: 10.3389/fmicb.2021.610080. eCollection 2021.
The colonization and persistence of probiotics introduced into the adult human gut appears to be limited. It is uncertain, however, whether probiotics can successfully colonize the intestinal tracts of full-term and premature infants. In this study, we investigated the colonization and the effect of oral supplementation with M-16V on the gut microbiota of low birth weight (LBW) infants. A total of 22 LBW infants (12 infants in the M-16V group and 10 infants in the control group) were enrolled. M-16V was administrated to LBW infants in the M-16V group from birth until hospital discharge. Fecal samples were collected from each subject at weeks (3.7-9.3 weeks in the M-16V group and 2.1-6.1 weeks in the control group) after discharge. qPCR analysis showed that the administrated strain was detected in 83.3% of fecal samples in the M-16V group (at log 8.33 ± 0.99 cell numbers per gram of wet feces), suggesting that this strain colonized most of the infants beyond several weeks post-administration. Fecal microbiota analysis by 16S rRNA gene sequencing showed that the abundance of Actinobacteria was significantly higher ( < 0.01), whereas that of Proteobacteria was significantly lower ( < 0.001) in the M-16V group as compared with the control group. Notably, the levels of the administrated strain and indigenous bacteria were both significantly higher in the M-16V group than in the control group. Our findings suggest that oral administration of M-16V led to engraftment for at least several weeks post-administration and we observed a potential overall improvement in microbiota formation in the LBW infants' guts.
引入成人体内肠道的益生菌的定植和持久性似乎有限。然而，益生菌能否成功定殖于足月儿和早产儿的肠道尚不确定。在本研究中，我们调查了口服补充M-16V对低出生体重（LBW）婴儿肠道微生物群的定植情况及影响。共纳入22名LBW婴儿（M-16V组12名婴儿，对照组10名婴儿）。M-16V组的LBW婴儿从出生至出院期间接受M-16V给药。出院后数周（M-16V组为3.7 - 9.3周，对照组为2.1 - 6.1周）从每个受试者采集粪便样本。qPCR分析显示，M-16V组83.3%的粪便样本中检测到给药菌株（每克湿粪便中细胞数为log 8.33 ± 0.99），表明该菌株在给药后数周内在大多数婴儿肠道中定殖。通过16S rRNA基因测序进行的粪便微生物群分析显示，与对照组相比，M-16V组中放线菌的丰度显著更高（<0.01），而变形菌的丰度显著更低（<0.001）。值得注意的是，M-16V组中给药菌株和本土细菌的水平均显著高于对照组。我们的研究结果表明，口服M-16V导致给药后至少数周的植入，并且我们观察到LBW婴儿肠道中微生物群形成有潜在的整体改善。
